news and
publicationspress releases
Press Releases
July 28, 2006
Synthetic Version of Scorpion Venom Delivers Radioactive Iodine to Malignant Brain Tumors
June 5, 2006
Study Demonstrates Safety of Promising Investigational Treatment for Deadly Brain Cancer
June 9, 2005
TransMolecular Appoints E. Michael Egan As Chief Executive Officer
June 1, 2005
TransMolecular Launches Phase II Clinical Study of 131I-TM601 to Treat Deadly Form of Brain Cancer
May 10, 2005
Board Changes Signal Continued Growth at TransMolecular
November 17, 2004
TransMolecular Broadens Patent Portfolio for Lead Oncology Products with Fifth Issued U.S. Patent
November 9, 2004
TransMolecular Obtains Patent for Key Biological Target Involved in Chronic Pain
August 27, 2003
TransMolecular Receives FDA Fast Track Designation for 131I-TM601, Its Lead Compound for Brain Cancer
September 4, 2002
TransMolecular Receives Patents to Protect Composition of Matter and Methods of Treating Cancer
June 27, 2002
FDA Grants TransMolecular Orphan Drug Designation for 131I-TM601 for Use by Glioma Patients
April 1, 2002
TransMolecular, Inc. Receives FDA Approval for 131I-TM601 IND Application